# PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

> **NCT01723774** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 84 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** PD0332991
- **DRUG:** Anastrozole
- **DRUG:** Goserelin
- **PROCEDURE:** Surgery (standard of care)
- **PROCEDURE:** Tumor biopsy

## Key facts

- **NCT ID:** NCT01723774
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-04-10
- **Primary completion:** 2021-04-13
- **Final completion:** 2026-08-24
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723774, "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01723774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*